Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Slideshows|August 17, 2021
The "Lorna Breen Act" in Short
Author(s)Grace Halsey
Click through a short summary of the provisions of the Dr Lorna Breen Health Care Provider Protection Act.
Advertisement
As the nation grapples with new COVI9-19 variants, mental health trauma specialists have
With forecasts like this one taken into consideration, the Dr Lorna Breen Healthcare Provider Protection Act, passed
Provisions of the Act, outlined on the Dr. Lorna Breen Heroes' Foundation web site, are summarized in the slides below.
Advertisement
Related to this article
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
FDA awarded DT120 Breakthrough Therapy designation for MDD based on phase 3 data showing rapid, sustained improvement after one 100 μg dose.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.
FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Advertisement
Advertisement
Trending on Patient Care Online
1
Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study
2
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
3
9 Drugs Approved for Primary Care: Q3 2026
4
Immunizing Against Pain and Fear: Rethinking the Vaccination Experience
5